Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections

Bioorg Med Chem Lett. 2019 Jul 1;29(13):1665-1672. doi: 10.1016/j.bmcl.2019.04.034. Epub 2019 Apr 24.


Current treatments for Mycobacterium tuberculosis infections require long and complicated regimens that can lead to patient non-compliance, increasing incidences of antibiotic-resistant strains, and lack of efficacy against latent stages of disease. Thus, new therapeutics are needed to improve tuberculosis standard of care. One strategy is to target protein homeostasis pathways by inhibiting molecular chaperones such as GroEL/ES (HSP60/10) chaperonin systems. M. tuberculosis has two GroEL homologs: GroEL1 is not essential but is important for cytokine-dependent granuloma formation, while GroEL2 is essential for survival and likely functions as the canonical housekeeping chaperonin for folding proteins. Another strategy is to target the protein tyrosine phosphatase B (PtpB) virulence factor that M. tuberculosis secretes into host cells to help evade immune responses. In the present study, we have identified a series of GroEL/ES inhibitors that inhibit M. tuberculosis growth in liquid culture and biochemical function of PtpB in vitro. With further optimization, such dual-targeting GroEL/ES and PtpB inhibitors could be effective against all stages of tuberculosis - actively replicating bacteria, bacteria evading host cell immune responses, and granuloma formation in latent disease - which would be a significant advance to augment current therapeutics that primarily target actively replicating bacteria.

Keywords: Antibiotics; Chaperonin; GroEL; GroES; HSP10; HSP60; Molecular chaperone; Mycobacterium tuberculosis; Phosphatases; Polypharmacology; Proteostasis; Small molecule inhibitors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Proteins / metabolism
  • Chaperonin 60 / pharmacology
  • Chaperonin 60 / therapeutic use*
  • Humans
  • Models, Molecular
  • Mycobacterium tuberculosis / pathogenicity*
  • Polypharmacology
  • Tuberculosis / drug therapy*


  • Bacterial Proteins
  • Chaperonin 60